dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:28:17Z
dc.date.available2014-05-27T11:28:17Z
dc.date.created2014-05-27T11:28:17Z
dc.date.issued2013-02-01
dc.identifierTumor Biology, v. 34, n. 1, p. 139-143, 2013.
dc.identifier1010-4283
dc.identifier1423-0380
dc.identifierhttp://hdl.handle.net/11449/74458
dc.identifier10.1007/s13277-012-0521-1
dc.identifierWOS:000313875400018
dc.identifier2-s2.0-84872783923
dc.description.abstractThe aim of this study was to investigate the expression of vascular endothelial growth factor type C (VEGF-C) in oral squamous cell carcinoma (OSCC) cell lines through norepinephrine-induced activation of beta-adrenergic receptors. Human OSCC cell lines (SCC-9 and SCC-25) expressing beta-adrenergic receptors were stimulated with different concentrations of norepinephrine (0.1, 1, and 10 μM) and 1 μM of propranolol, and analyzed after 1, 6, and 24 h. VEGF-C gene expression and VEGF-C production in the cell supernatant were evaluated by real-time PCR and by ELISA, respectively. The results showed that beta-adrenergic receptor stimulation by different concentrations of norepinephrine or blocking by propranolol did not markedly alter VEGF-C expression by SCC-9 and SCC-25 cells. VEGF-C protein levels produced by oral malignant cell lines after stimulation with different norepinephrine concentrations or blocking with propranolol was statistically similar (p > 0.05) to those of the control group (nonstimulated OSCC cell lines). Our findings suggest that stimulation of beta-adrenergic receptors by means of norepinephrine does not seem to modulate the VEGF-C expression in OSCC cell lines. These findings reinforce the need for further studies in order to understand the responsiveness of oral cancer to beta-adrenergic receptor stimulation or blockage, especially with regard to VEGF-C production. © 2012 International Society of Oncology and BioMarkers (ISOBM).
dc.languageeng
dc.relationTumor Biology
dc.relation1,149
dc.relation1,149
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectAdrenergic receptors
dc.subjectOral cancer
dc.subjectVEGF
dc.subjectbeta adrenergic receptor
dc.subjectnoradrenalin
dc.subjectpropranolol
dc.subjectvasculotropin C
dc.subjectcancer cell
dc.subjectcancer cell culture
dc.subjectcell line SCC 25
dc.subjectcell line SCC 9
dc.subjectcontrolled study
dc.subjectenzyme activation
dc.subjectenzyme activity
dc.subjectenzyme synthesis
dc.subjecthuman
dc.subjecthuman cell
dc.subjectin vitro study
dc.subjectmouth squamous cell carcinoma
dc.subjectpriority journal
dc.subjectprotein analysis
dc.subjectprotein expression
dc.subjectprotein function
dc.subjectAdrenergic beta-Antagonists
dc.subjectCarcinoma, Squamous Cell
dc.subjectCell Line, Tumor
dc.subjectHumans
dc.subjectMouth Neoplasms
dc.subjectNeurotransmitter Agents
dc.subjectNorepinephrine
dc.subjectPropranolol
dc.subjectReceptors, Adrenergic, beta
dc.subjectVascular Endothelial Growth Factor C
dc.titleVEGF-C expression in oral cancer by neurotransmitter-induced activation of beta-adrenergic receptors
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución